Uveal (Ocular) Melanoma Pipeline Analysis 2019 (H1)

Published: Mar 2020 | Report Code:  KSI061611483 | Pages:  114

Uveal (Ocular) Melanoma Pipeline Analysis report covers 8 drugs currently in different phases of development. Uveal melanoma develops from the melanocyte cells in the eyes which are found in the uveal tract comprised of choroid, ciliary body and iris. The cause of the disease is yet not known, however it is more prevalent in Caucasians. The symptoms includes blurred vision, flashing lights or or a shadow in the eye. Treatment options includes brachytherapy, radiotherapy, photodynamic therapy and enucleation.

The report provides uveal melanoma treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Novartis AG, Aura Biosciences, Inc., Bellicum Pharmaceuticals, Inc., and Iconic Therapeutics, Inc. among others.


  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration

*There may be changes in the final report as per the data availability